Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.

ABSTRACT:

Importance

Patient-reported outcome (PRO) assessments alongside clinical parameters help to holistically determine treatment benefits.

Objective

To assess PROs among bimekizumab-treated patients with moderate to severe plaque psoriasis.

Design, setting, and participants

The BE RADIANT multicenter, phase 3b randomized clinical trial and open-label extension (OLE) had a 48-week double-blinded period and 96-week OLE (3 years' total treatment). Patients initially received bimekizumab or secukinumab. At year 1 (week 48/OLE entry), bimekizumab-randomized patients continued bimekizumab treatment (continuous bimekizumab-treated patients) and secukinumab-randomized patients switched to bimekizumab (secukinumab/bimekizumab-treated patients).

Interventions

Continuous bime

SUBMITTER: Augustin M 

PROVIDER: S-EPMC12917748 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature